30 Oct 2017 10:08
Premaitha Health plc
("Premaitha" or the "Company")
Grant of share options
Manchester, UK - 30 October 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing ("NIPT"), announces that it has made a grant of share options.
The Company has today issued 3,825,000 options over ordinary shares under the Company's Enterprise Management Incentive (EMI) and unapproved share option schemes to a number of managers and key staff in lieu of cash bonuses ("New Options").
The New Options are exercisable in three tranches over three financial years and are subject to certain performance conditions, with the options being exercisable up to 29 October 2027, at a price of 10 pence per share.
Following the issue of the New Options, and taking into account lapsed options, the Company has 40,046,830 shares under option and a further 86,094,192 shares under warrant. The issued share capital of the Company comprises 321,218,279 Ordinary Shares of 0.1p each.
For more information, please contact:
Premaitha Health plc | Tel: +44 (0) 161 667 6865 |
Dr Stephen Little, Chief Executive Office | |
Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing | |
investors@premaitha.com | |
Cairn Financial Advisers LLP (Nomad) | Tel: +44 (0) 20 7213 0880 |
Liam Murray / James Caithie | |
finnCap (Broker) | Tel: +44 (0) 20 7220 0500 |
Adrian Hargrave / Scott Mathieson (Corporate Finance) | |
Tony Quirke (Corporate Broking) | |
Vigo Communications | Tel: +44 (0) 20 7830 9701 |
Ben Simons / Fiona Henson / Antonia Pollock | |
premaitha@vigocomms.com |
About Premaitha
Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.
Premaitha's IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.
Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.